Agenus Inc. (AGEN) Financials

AGEN Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 186.5 million 414.4 million
Dec. 31, 2025 226.8 million 504.7 million
Sept. 30, 2025 233.9 million 514.8 million
June 30, 2025 185.2 million 521.5 million

AGEN Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -36.0 million 1.1 million
Dec. 31, 2025 -16.6 million 3.5 million
Sept. 30, 2025 -14.7 million 3.2 million
June 30, 2025 -20.2 million 3.6 million

AGEN Net Income

No data available :(

AGEN Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 35.0 million 154.0 million 9.8 million
Dec. 31, 2025 3.0 million 169.7 million 10.1 million
Sept. 30, 2025 3.5 million 23.6 million 11.6 million
June 30, 2025 9.5 million 23.2 million 57.4 million

AGEN Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 38.3 million
Dec. 31, 2025 35.3 million
Sept. 30, 2025 32.9 million
June 30, 2025 28.1 million

AGEN Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 11.8 million 6.9 million -
Dec. 31, 2025 582000 7.5 million 12.3 million -
Sept. 30, 2025 6000 - 10.9 million -
June 30, 2025 1000 26.7 million 15.5 million -

AGEN Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 33.7 million 583000
Dec. 31, 2025 34.2 million 7.5 million
Sept. 30, 2025 30.2 million 24.2 million
June 30, 2025 25.7 million 27.0 million

AGEN Revenue by Segment
Graph available only for paid members. Upgrade to see it.

AGEN

Price: $2.98

52 week price:
2.71
7.34

Payout Ratio Range:
-49814.29%
2920.16%

Earnings Per Share: 2.05 USD

P/E Ratio: 1.75

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 207310

Ebitda: -30.2 million

Market Capitalization: 134.1 million

Links: